Abstract
Regardless of the degree of glycemic control, Linagliptin (LINA) has lower hypoglycemia risk than all doses of Glimepiride (GLIM), at all timeg points over a 2-year trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have